Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Goldberg

Showing results (971-980 of 1,004) with videos related to

Pageof 101
Sort By:
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
European Urology|April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 TrialMinas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Nature|October 29, 2020
Single-cell mutation analysis of clonal evolution in myeloid malignanciesLinde A Miles, Robert L Bowman, Tiffany R Merlinsky, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Blood|September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemiaWenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
AIDS and Behavior|November 11, 2022
Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and IsraelLucas Wiessing, V Sypsa, A O Abagiu, et al.
Cancer Discovery|July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 InhibitionSheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Pageof 101

Showing results (971-980 of 1,004) with videos related to

Sort By:
Pageof 101
Blood Advances|June 28, 2024
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLJan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, et al.
European Urology|April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 TrialMinas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Nature|October 29, 2020
Single-cell mutation analysis of clonal evolution in myeloid malignanciesLinde A Miles, Robert L Bowman, Tiffany R Merlinsky, et al.
Blood Neoplasia|March 20, 2026
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogeneticsLuis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Blood|September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemiaWenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
AIDS and Behavior|November 11, 2022
Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and IsraelLucas Wiessing, V Sypsa, A O Abagiu, et al.
Cancer Discovery|July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 InhibitionSheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Pageof 101